Specialized Disclosure Report (sd)
June 18 2018 - 4:02PM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
Specialized Disclosure Report
Precision Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Commission File Number:
001-36790
Delaware
|
|
33-1007393
|
(State or other jurisdiction of
|
|
(I.R.S. Employer
|
incorporation or organization)
|
|
Identification No.)
|
|
|
|
2915 Commers Drive, Suite 900
|
|
Eagan, Minnesota 55121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Bob Myers 651-389-4800
(Registrant’s name and telephone number, including area code,
of the person to contact
in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed,
and provide the period to which the information in this form applies:
☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the
reporting period from January 1 to December 31, 2017.
Section 1 – Conflict Minerals Disclosure
Precision Therapeutics Inc. (“Precision”, “we”, “our”
or the “Company”) has evaluated its current product lines and determined that certain products we manufacture contain
tin, tungsten, tantalum and/or gold (3TG), which are defined as “conflict minerals” by the United States Securities
and Exchange Commission that are necessary to the functionality or production of our products. Accordingly, we are filing this
disclosure along with a Conflict Minerals Report to disclose the measures we have taken to determine the origin of the conflict
minerals used in our products.
Item 1.01 Conflict Minerals Disclosure
We undertook due diligence measures, including surveying our direct suppliers to try
to determine the sources of these minerals, which we purchase through a complex supply chain.
We currently still have 30% of our suppliers who are not able to identify the mineral
sources’ originating country. Therefore, we cannot exclude the possibility that some of these conflict minerals may have
originated in the Democratic Republic of the Congo or an adjoining country and are not from recycled or scrap sources.
Item 1.02 Exhibit
A copy of the Company’s Conflict Minerals Report for the reporting period from
January 1, 2017 to December 31, 2017 is provided as Exhibit 1.01 hereto and is publicly available at: www.skylinemedical.com under
News and Media. The content of any website referred to in this Form SD is included for general information only and is not incorporated
by reference in this Form SD.
Section 2 - Exhibits
Exhibit 1.01
– Conflict Minerals Report as required by Items 1.01 and 1.02 of this
Form.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the duly authorized undersigned.
Precision Therapeutics Inc.
|
|
|
|
|
|
By: /s/ Bob Myers
|
|
Date: June 18, 2018
|
|
|
|
Name: Bob Myers
|
|
|
Title: Chief Financial Officer
|
|
|
3
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2023 to Apr 2024